Which has better valuation & earnings, SRRK or AVBP?

Scholar Rock is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.45 N/A ArriVent BioPharma N/A N/A -$166.31M -$3.62 N/A

Is SRRK or AVBP more profitable?

ArriVent BioPharma's return on equity of -50.26% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% ArriVent BioPharma N/A -50.26% -46.66%

Does the media prefer SRRK or AVBP?

In the previous week, Scholar Rock had 12 more articles in the media than ArriVent BioPharma. MarketBeat recorded 16 mentions for Scholar Rock and 4 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.08 beat Scholar Rock's score of 0.72 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LGND or AVBP?

In the previous week, Ligand Pharmaceuticals had 6 more articles in the media than ArriVent BioPharma. MarketBeat recorded 10 mentions for Ligand Pharmaceuticals and 4 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.08 beat Ligand Pharmaceuticals' score of 0.60 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AVBP or CRSP?

In the previous week, CRISPR Therapeutics had 10 more articles in the media than ArriVent BioPharma. MarketBeat recorded 14 mentions for CRISPR Therapeutics and 4 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.08 beat CRISPR Therapeutics' score of 0.63 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, COGT or AVBP?

Cogent Biosciences is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.16 N/A ArriVent BioPharma N/A N/A -$166.31M -$3.62 N/A

Is COGT or AVBP more profitable?

ArriVent BioPharma's return on equity of -50.26% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -84.47% -47.72% ArriVent BioPharma N/A -50.26% -46.66%

Does the media favor COGT or AVBP?

In the previous week, ArriVent BioPharma had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for ArriVent BioPharma and 2 mentions for Cogent Biosciences. ArriVent BioPharma's average media sentiment score of 1.08 beat Cogent Biosciences' score of 0.27 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ArriVent BioPharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PTCT or AVBP?

In the previous week, PTC Therapeutics had 10 more articles in the media than ArriVent BioPharma. MarketBeat recorded 14 mentions for PTC Therapeutics and 4 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.08 beat PTC Therapeutics' score of 0.51 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ArriVent BioPharma (AVBP) Competitors

$30.30 -0.02 (-0.07%)

Closing price 04:00 PM Eastern

Extended Trading

$30.27 -0.03 (-0.10%)

As of 07:30 PM Eastern

Compare

AVBP vs. SRRK, LGND, CRSP, COGT, and PTCT

Should you buy ArriVent BioPharma stock or one of its competitors? ArriVent BioPharma's main competitors and comparable companies include Scholar Rock (SRRK), Ligand Pharmaceuticals (LGND), CRISPR Therapeutics (CRSP), Cogent Biosciences (COGT), and PTC Therapeutics (PTCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ArriVent BioPharma compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Scholar Rock had 12 more articles in the media than ArriVent BioPharma. MarketBeat recorded 16 mentions for Scholar Rock and 4 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.08 beat Scholar Rock's score of 0.72 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ArriVent BioPharma's return on equity of -50.26% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
ArriVent BioPharma	N/A	-50.26%	-46.66%

Scholar Rock is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

Scholar Rock presently has a consensus price target of $66.69, suggesting a potential upside of 33.78%. ArriVent BioPharma has a consensus price target of $44.86, suggesting a potential upside of 48.04%. Given ArriVent BioPharma's higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	2.94
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Scholar Rock has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

Summary

Scholar Rock and ArriVent BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

How does ArriVent BioPharma compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Ligand Pharmaceuticals has a net margin of 67.88% compared to ArriVent BioPharma's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
ArriVent BioPharma	N/A	-50.26%	-46.66%

Ligand Pharmaceuticals has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	22.20	$124.45M	$9.35	31.92
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

Ligand Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ligand Pharmaceuticals currently has a consensus target price of $337.00, indicating a potential upside of 12.93%. ArriVent BioPharma has a consensus target price of $44.86, indicating a potential upside of 48.04%. Given ArriVent BioPharma's higher possible upside, analysts clearly believe ArriVent BioPharma is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, Ligand Pharmaceuticals had 6 more articles in the media than ArriVent BioPharma. MarketBeat recorded 10 mentions for Ligand Pharmaceuticals and 4 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.08 beat Ligand Pharmaceuticals' score of 0.60 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ligand Pharmaceuticals beats ArriVent BioPharma on 11 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to CRISPR Therapeutics?

ArriVent BioPharma (NASDAQ:AVBP) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

ArriVent BioPharma has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, CRISPR Therapeutics had 10 more articles in the media than ArriVent BioPharma. MarketBeat recorded 14 mentions for CRISPR Therapeutics and 4 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.08 beat CRISPR Therapeutics' score of 0.63 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ArriVent BioPharma has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

ArriVent BioPharma presently has a consensus target price of $44.86, suggesting a potential upside of 48.04%. CRISPR Therapeutics has a consensus target price of $67.94, suggesting a potential upside of 21.85%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, equities analysts plainly believe ArriVent BioPharma is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.59

ArriVent BioPharma has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
CRISPR Therapeutics	$11M	490.15	-$581.60M	-$4.76	N/A

Summary

ArriVent BioPharma and CRISPR Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does ArriVent BioPharma compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

9.5% of ArriVent BioPharma shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, ArriVent BioPharma had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 4 mentions for ArriVent BioPharma and 2 mentions for Cogent Biosciences. ArriVent BioPharma's average media sentiment score of 1.08 beat Cogent Biosciences' score of 0.27 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ArriVent BioPharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

Cogent Biosciences presently has a consensus target price of $51.56, suggesting a potential upside of 64.14%. ArriVent BioPharma has a consensus target price of $44.86, suggesting a potential upside of 48.04%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Cogent Biosciences is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

ArriVent BioPharma's return on equity of -50.26% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
ArriVent BioPharma	N/A	-50.26%	-46.66%

Cogent Biosciences is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

Summary

ArriVent BioPharma beats Cogent Biosciences on 9 of the 13 factors compared between the two stocks.

How does ArriVent BioPharma compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and ArriVent BioPharma (NASDAQ:AVBP) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

ArriVent BioPharma has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%. ArriVent BioPharma's return on equity of -50.26% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
ArriVent BioPharma	N/A	-50.26%	-46.66%

PTC Therapeutics has higher revenue and earnings than ArriVent BioPharma. PTC Therapeutics is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.01	$682.64M	-$0.58	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A

PTC Therapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

PTC Therapeutics presently has a consensus price target of $99.08, suggesting a potential upside of 58.94%. ArriVent BioPharma has a consensus price target of $44.86, suggesting a potential upside of 48.04%. Given PTC Therapeutics' higher probable upside, equities analysts clearly believe PTC Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

9.5% of ArriVent BioPharma shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, PTC Therapeutics had 10 more articles in the media than ArriVent BioPharma. MarketBeat recorded 14 mentions for PTC Therapeutics and 4 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.08 beat PTC Therapeutics' score of 0.51 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PTC Therapeutics and ArriVent BioPharma tied by winning 8 of the 16 factors compared between the two stocks.

Get ArriVent BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVBP vs. The Competition

Export

Metric	ArriVent BioPharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.49B	$3.90B	$7.21B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	13.00%
P/E Ratio	-8.37	13.95	274.58	25.69
Price / Sales	N/A	1,386.64	648.78	85.88
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	4.07	15.30	10.44	6.32
Net Income	-$166.31M	-$22.82M	$3.49B	$359.73M
7 Day Performance	9.58%	-0.22%	0.51%	1.35%
1 Month Performance	4.05%	-6.06%	-3.38%	-3.68%
1 Year Performance	65.85%	34.37%	16.04%	5.56%

ArriVent BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVBP ArriVent BioPharma	2.5672 of 5 stars	$30.30 -0.1%	$44.86 +48.0%	+62.8%	$1.49B	N/A	N/A	77	Positive News Analyst Forecast High Trading Volume
SRRK Scholar Rock	3.66 of 5 stars	$51.19 +6.3%	$66.69 +30.3%	+57.1%	$5.87B	N/A	N/A	289	Analyst Forecast Gap Down
LGND Ligand Pharmaceuticals	3.3996 of 5 stars	$298.50 +2.9%	$335.75 +12.5%	+74.8%	$5.78B	$268.09M	31.93	47	News Coverage Positive News Analyst Upgrade
CRSP CRISPR Therapeutics	2.7472 of 5 stars	$59.03 +1.2%	$67.94 +15.1%	-4.9%	$5.64B	$3.51M	N/A	393	Insider Trade
COGT Cogent Biosciences	2.0259 of 5 stars	$32.63 +2.0%	$51.56 +58.0%	+160.8%	$5.55B	N/A	N/A	258

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVBP) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ArriVent BioPharma (AVBP) Competitors

AVBP vs. SRRK, LGND, CRSP, COGT, and PTCT

How does ArriVent BioPharma compare to Scholar Rock?

Summary

How does ArriVent BioPharma compare to Ligand Pharmaceuticals?

Summary

How does ArriVent BioPharma compare to CRISPR Therapeutics?

Summary

How does ArriVent BioPharma compare to Cogent Biosciences?

Summary

How does ArriVent BioPharma compare to PTC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ArriVent BioPharma (AVBP) Competitors

AVBP vs. SRRK, LGND, CRSP, COGT, and PTCT

How does ArriVent BioPharma compare to Scholar Rock?

Does the media prefer SRRK or AVBP?

Do institutionals and insiders hold more shares of SRRK or AVBP?

Is SRRK or AVBP more profitable?

Which has better valuation & earnings, SRRK or AVBP?

Do analysts rate SRRK or AVBP?

Which has more volatility & risk, SRRK or AVBP?

Summary

How does ArriVent BioPharma compare to Ligand Pharmaceuticals?

Is LGND or AVBP more profitable?

Which has preferable valuation and earnings, LGND or AVBP?

Which has more volatility & risk, LGND or AVBP?

Do institutionals & insiders have more ownership in LGND or AVBP?

Do analysts prefer LGND or AVBP?

Does the media favor LGND or AVBP?

Summary

How does ArriVent BioPharma compare to CRISPR Therapeutics?

Which has more risk and volatility, AVBP or CRSP?

Do insiders and institutionals hold more shares of AVBP or CRSP?

Does the media favor AVBP or CRSP?

Is AVBP or CRSP more profitable?

Do analysts rate AVBP or CRSP?

Which has better earnings & valuation, AVBP or CRSP?

Summary

How does ArriVent BioPharma compare to Cogent Biosciences?

Do institutionals and insiders hold more shares of COGT or AVBP?

Does the media favor COGT or AVBP?

Which has more volatility and risk, COGT or AVBP?

Do analysts recommend COGT or AVBP?

Is COGT or AVBP more profitable?

Which has higher earnings & valuation, COGT or AVBP?

Summary

How does ArriVent BioPharma compare to PTC Therapeutics?

Is PTCT or AVBP more profitable?

Which has higher valuation and earnings, PTCT or AVBP?

Which has more risk and volatility, PTCT or AVBP?

Do analysts rate PTCT or AVBP?

Do institutionals & insiders have more ownership in PTCT or AVBP?

Does the media prefer PTCT or AVBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools